Idera Pharmaceuticals reports third quarter 2012 financial results (Idera Pharmaceuticals, Inc) - Nov 12, 2012 - Anticipated top line P2 data by year-end 2012
Anticipated P2 data • Psoriasis
|
|
Recent Business and Clinical Highlights
In the third quarter of 2012, the Company completed enrollment in a Phase 2 randomized, double-blind, placebo-controlled, multi-center clinical trial of IMO-3100 in patients with moderate to severe plaque psoriasis.
---
The Company anticipates reporting top-line data for some of the endpoints of the trial by year-end 2012.
|